Background: While cannabis use and its relationship with cognitive functioning has been studied extensively in patients with schizophrenia, little is known about the association between stimulant use (amphetamines, cocaine, ecstasy) and cognitive functioning. The current study examined (1) whether recency and frequency of stimulant use is associated with cognitive functioning, and (2) whether these associations differ between patients with psychotic disorder, their unaffected siblings and controls.
INTRODUCTION
Substance use and substance use disorder are common phenomena in patients with schizophrenia, with prevalence estimates ranging between 10 and 70% (Barnes et al., 2006; Dixon et al., 1991; Mazzoncini et al., 2010; Mueser et al., 1990; Regier et al., 1990 ). This increased prevalence may reflect some shared neurobiological vulnerability for substance use disorders and schizophrenia (Chambers et al., 2001 ). Comorbid substance use disorder among patients diagnosed with schizophrenia is associated with greater symptom severity, poorer prognosis and more hospital admissions (Linszen et al., 1994; Moore et al., 2007; Swofford et al., 2000; van Dijk et al., 2012) . Higher rates of substance abuse have also been reported in unaffected relatives of schizophrenia patients compared to healthy controls (Smith et al., 2008; Varma & Sharma, 1993) , suggesting that the liability to abuse substances may be partly familial.
Over the last two decades, cannabis use has been the main target in studies concerning substance use in patients with schizophrenia (Henquet et al., 2010; van Os et al., 2010) . Many of these studies have specifically focused on the association between cannabis use and cognitive alterations (e.g. memory, attention, processing speed, learning and cognitive planning). The relationship between cannabis use in patients with schizophrenia and cognitive function seems to depend on differences in time and frequency of use and the domain of cognitive functioning (Coulston et Relatively little is known about the relationship between cognitive functioning and the use of illicit drugs other than cannabis, such as cocaine (Buckley, 1998) , 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy'; Landry, 2002) and amphetamines (Fowler et al., 1998) in patients with schizophrenia. These stimulant drugs constitute the group of the second-most popular illicit substances in patients with schizophrenia (Coyle, 2006) , with prevalence rates ranging from 18 up to 36% (Shaner et al., 1993; van Dijk et al., 2012) . Cocaine and amphetamines are both known to influence the dopaminergic system. They increase the levels of free dopamine in the brain in a dose-dependent manner: higher dosages of stimulants lead to more dopamine available and greater feelings of elation, euphoria and satisfaction (Center for Substance Abuse Treatment, 1999). Although not directly, evidence suggests that MDMA also influences the dopaminergic system in the brain through the interaction with the serotonergic system. As a consequence, stimulant use may be associated with development of psychosis and with aggravation of psychotic symptoms in this patient group (Barnett et Richard et al., 1985) . Also in the general population, stimulant use has been found to produce brief psychotic reactions independent of the individual's mental state prior to the use of stimulants (Curran et al., 2004) .
In addition to these psychotomimetic effects, the use of stimulants has also been associated with cognitive alterations. In general population samples, most consistent deficits have been reported in working memory, attention, executive functioning, motor speed, verbal learning and information processing (Block et al., 2002; Fernandez-Serrano et al., 2011; Toomey et al., 2003; van Holst & Schilt, 2011) . At the same time, stimulant use has been found to enhance performance on certain types of psychomotor and concentration tasks (Center for Substance 40 Abuse Treatment, 1999). In schizophrenia, contradictory findings have been reported, with both worse and superior cognitive performance associated with the use of stimulants. It therefore remains unclear whether the use of stimulants is associated with a further cognitive decline in patients diagnosed with schizophrenia and/or with an enhancement of performance in certain domains (Reichenberg & Harvey, 2007; Tuulio-Henriksson et al., 2011) . In studies on the cognitive effects of substance abuse in schizophrenia, the effects of disease related factors like psychotic symptoms and medication need to be taken into account as possible confounders of the relationship between substance use and cognitive functioning. One way to address this problem is to evaluate the effect of substance use in unaffected siblings of patients with a psychosis.
The present study aims to examine the association between current and lifetime stimulant use and cognitive functioning in patients diagnosed with a non-affective psychotic disorder, their unaffected siblings and healthy controls while correcting for the possible confounding effects of cannabis, psychedelics, other illicit substance use and heavy alcohol use (Coulston et al., 2007) . In addition, we used smoking as a covariate, since nicotine also exerts an effect on brain and cognition (Coulston et al., 2007) . In short, we aimed to examine (1) whether recency and frequency of stimulant use is significantly associated with alterations in cognitive functioning and (2) whether the association between stimulant use and cognitive functioning is different in patients, their unaffected siblings and controls. We hypothesized that both current and lifetime stimulant use is associated with more impairments in cognitive functioning. Based on the findings in studies on cannabis, we expected this association to be stronger for current and lifetime frequent use compared to lifetime infrequent use. Because of previous inconsistent results with regard to cognitive functioning and stimulant use in schizophrenia patients and healthy controls, we did not expect to find an interaction effect between stimulant use and diagnostic status.
METHODS

Participants
In this cross-sectional study 2,691 subjects were included: 1,077 patients with non-affective psychosis, 1,032 siblings and 582 healthy controls. Data pertain to baseline measures of GROUP (Genetic Risk and Outcome of Psychosis), a longitudinal study in the Netherlands and Belgium (Korver et al., 2012) . In selected representative geographical areas patients were identified through clinicians working in psychotic disorder services whose caseloads were screened for individuals meeting the inclusion criteria. Additionally, a group of patients presenting consecutively at these services as either outpatients or inpatients were recruited for the study. Patients were asked for permission to contact their siblings. Controls were selected through a system of random mailings to addresses in the catchment areas of the cases.
Inclusion criteria for patients, siblings and controls were (1) age 16-50 years and (2) good command of the Dutch language. Patients had to meet DSM-IV-TR criteria (APA, 2000) for a non-affective psychotic disorder which was assessed with the Comprehensive Assessment of Symptoms and History (CASH; Andreasen et al., 1992) or the Schedules for Clinical Assessment in Neuropsychiatry version 2.1 (SCAN; Wing et al., 1990) . Exclusion criteria for siblings were a history of psychotic disorder or bipolar disorder. Exclusion criteria for healthy controls were a history of psychotic disorder or a first-degree family member with a history of psychotic disorder.
The study protocol was approved centrally by the Ethical Review Board of the University Medical Centre Utrecht and subsequently by local review boards of each participating institute. All of the subjects gave written informed consent in accordance with the committee's guidelines.
Cognitive Measures
Subjects were assessed with a neuropsychological test battery, which required 90 to 120 minutes to complete. The 10 cognitive tasks yielded 13 outcome parameters, which were used as dependent variables in the analyses.
Verbal learning was assessed making use of the Word Learning Task 
Assessment of symptoms and substance use
Severity of psychotic symptoms in patients was rated with the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) . In relatives and controls, the Community Assessment of Psychic Experiences (CAPE; Stefanis et al., 2002) was used to examine (subclinical) positive, negative and depressive symptoms on both a frequency scale (0=never to 3=nearly always) and a distress scale (0=not distressed to 3=very distressed).
Substance use was assessed by means of the Comprehensive International Diagnostic Interview (CIDI; WHO, 1990 ) and with urinalysis. Stimulant use (ecstasy, cocaine, amphetamine) was categorized as either current use (urinalysis positive) or lifetime but no current use (negative urinalysis plus positive self report on the CIDI for amphetamines, cocaine or ecstasy with a frequency of 5 times or more). In order to investigate the possibility of a dose-response relationship, lifetime stimulant use was subdivided into lifetime frequent use (daily or weekly use on the CIDI) and lifetime infrequent use (less than weekly use on the CIDI). The detection period for the urinalysis was 2-4 days for cocaine and 1-2 days for amphetamines and ecstasy.
Statistical analyses
Differences in demographic and substance-use characteristics between patients, siblings and controls were tested with one-way analysis of variance and chi square tests. Differences in demographic and clinical characteristics between current, lifetime frequent, lifetime infrequent and never users were tested within patient, sibling and control groups by means of one-way analysis of variance and chi square tests with a significance level of .05.
The association between stimulant use and cognitive functioning was assessed with mixed-model regression analyses. In a first step we built random effect regression models with each cognitive outcome measure as dependent variable. Stimulant use (current, lifetime frequent, lifetime infrequent, never), Diagnostic Status (patient, sibling, control) and the Stimulant use by Status interaction term were entered as fixed part of the model. Because of intra-family dependency between patients and siblings, "family number" was entered into the regression model as a random factor with a random intercept. In the second step, the following covariates were entered into the model: age, gender, highest educational level (ranging from 1 = primary school to 8 = university), use of cannabis, psychedelics, or other illicit substances (e.g. sedatives, inhalants, PCP), smoking, and heavy alcohol use (with a cut-off for females and males of 14, respectively 21 units per week). In case the interaction term was not statistically significant, the model and analyses were repeated without the interaction term. Due to the high power caused by the large n, effect sizes (Cohen's d) were calculated to distinguish relevant effects from trivial but statistical significant effects. All analyses were performed with SPSS (version 17.0). For the group comparisons the significance level was set at .05, for the random effect analyses a correction for multiple comparisons was applied by setting the alpha at .005.
RESULTS
Demographic and clinical variables
As presented in Table 1 , patients and unaffected siblings were significantly younger than controls. Patients were more often male compared to siblings and controls. Highest level of education was significantly lower in patients compared to siblings and controls. Moreover, patients were more often than siblings and controls lifetime users of stimulants (25.6% vs. 9.5% vs. 5.8%), cannabis (64.6% vs. 39.0% vs. 28.0%), psychedelics (8.8% vs. 5.4% vs. 3.8%), other illicit substances (8.9% vs. 3.1% vs. 2.6%), and nicotine (66.0% vs. 37.9% vs. 24.7%). Heavy alcohol use was not significantly different between the diagnostic groups. Table 2a shows demographic and clinical characteristics of current, lifetime frequent, lifetime infrequent and never stimulant using patients. Stimulant using patients were significantly younger, more often male and lower educated in comparison to never users. Age at onset of psychosis was younger in stimulant users compared to never users. Stimulant using patients were more often lifetime users of cannabis, psychedelics, other illicit substances, heavy alcohol and nicotine. Stimulant use was not significantly associated with remission rate, the use of antipsychotics, or illness duration. Table 2b and 2c show characteristics of current, lifetime frequent, lifetime infrequent and never stimulant using siblings and controls. Stimulant using siblings were younger, more often male and lower educated. They were more often lifetime users of cannabis, psychedelics, other illicit substances, heavy alcohol and nicotine. Stimulant using controls were more often male and more often users of cannabis, psychedelics, other illicit substances and nicotine. Age, educational level and heavy alcohol use were not significantly different between stimulant using and non-using controls.
Associations between stimulant use and cognitive functioning
The interaction term between Stimulant use (current, lifetime frequent, lifetime infrequent, never) and Diagnostic Status (patient, sibling, control) was not significant for any of the cognitive outcome parameters, indicating similar effects of stimulant use in all three groups. Consequently, the interaction term was removed from the random effect regression models for the final analyses. The effects of stimulant use displayed in Figure 1 therefore apply to the total group of patients, siblings and controls. 
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Discussion
In the present study, we examined the association between current and lifetime stimulant use and cognitive functioning in a large sample of patients diagnosed with a non-affective psychotic disorder, their unaffected siblings and healthy Current stimulant use was associated with a general pattern of non-significantly worse cognitive functioning compared to never use. Current stimulant users only performed significantly worse than never users on the number of incorrect words in the Word Learning Task (Cohen's d -0.60; F(3,2239)=6.28; p<.005).
Lifetime frequent (i.e. daily to weekly) stimulant use was associated with significant worse performance on a range of cognitive tasks compared to never stimulant use, including associations with immediate recall in the Word Learning Task (F(3,2573) =4.39; p<.005), delayed recall in the Word Learning Task (F(3,2540) =7.21; p<.005), WAIS Arithmetic (F(3,2535) =2.91; p<.005) and WAIS Information (F(3,2424) =6.19; p<.005), although effect sizes were small (Cohen's d -0.22 to -0.29). Associations with the number of incorrect words in the Word Learning Task, as well as the association with WAIS Digit Symbol-coding did not survive correction for multiple comparisons. Although lifetime infrequent (less than weekly) stimulant use was associated with a general pattern of better cognitive functioning in comparison to never use, these results did not reach statistical significance and effect sizes were small (Cohen's d +0.10).
DISCUSSION
In the present study, we examined the association between current and lifetime stimulant use and cognitive functioning in a large sample of patients diagnosed with a non-affective psychotic disorder, their unaffected siblings and healthy controls while taking into account important potential confounders such as age, gender, educational level and other substance use. In general our hypotheses were confirmed. First, similar associations between stimulant use and cognition were found in patients, siblings and controls. Second, both current and lifetime frequent stimulant use was associated with worse cognitive functioning in specific domains of immediate and delayed verbal learning (WLT), working memory (WAIS Arithmetic) and acquired knowledge (WAIS Information). Third, in the infrequent stimulant-using group, an insignificant trend for better cognitive functioning was observed.
The finding that lifetime frequent stimulant use was associated with worse cognitive functioning in specific cognitive domains is consistent with several previous studies in patients with schizophrenia (Pencer & Rosselli & Ardila, 1996) . Furthermore, our study indicates worse cognitive functioning in unaffected siblings who frequently use stimulants in comparison to never users. To our knowledge, this is the first time that this association has been investigated in unaffected siblings.
Additionally, our results in current stimulant using patients are in line with a previous study that reported an association between current stimulant use and impaired verbal memory in a sample of schizophrenia patients . Although not significant, we found a trend for worse cognitive functioning in current users on several other cognitive domains. The lack of significant associations in this group could be the result of insufficient power, since only 32 subjects were current stimulant users. However, other studies neither found (additional) cognitive impairments in current stimulant using schizophrenia patients (Cooper et , 2005) , the association between lifetime infrequent stimulant use and better cognition in our study was small and insignificant. It has been suggested that patients who use substances need better cognitive skills to obtain drugs, which may explain higher levels of premorbid adjustment in comparison to never using patients (Murray et al., 1992) . However, in the Netherlands stimulants are relatively cheap and easy to obtain, which makes such a selection effect less likely. Stimulant using and never using patients did not differ in illness duration, use of antipsychotics and number of relapses, suggesting that the effect on disease course may be limited in patients with a non-affective psychotic disorder. However, prospective studies are needed to confirm this preliminary impression.
Methodological differences are likely to have contributed to inconsistencies between our results and those previously reported. First, variation in the type of stimulants may explain some of the different findings. Second, in the abovementioned studies, different tests have been used to determine verbal learning, processing speed and working memory. This heterogeneity in neuropsychological testing is a general problem that limits comparability and requires the use of more standardized cognitive test batteries. Comparability between studies would be further advanced by formulating clearer definitions of recency and frequency of substance use. And finally, the use of urinalysis versus self-report measures may account for differences in study results.
Our findings should be interpreted in light of some limitations. Although we corrected for the use of other illicit substances, alcohol, and nicotine, it is possible that a group of 'pure' stimulant users would have shown different results regarding associations with cognition. However, this study was designed to take place in a naturalistic context in which single drug use is exceptional. In addition, we used a rather rough division into 'daily', 'weekly' and 'less than weekly use' for measuring the frequency of stimulant use conform the criteria in the CIDI (WHO, 1990) . In future studies, the use of a continuous measure is recommended (e.g. number of times used, total amount used). Moreover, although the choice to combine amphetamine, cocaine and ecstasy into one measure increases power, it may restrict comparability to other studies. On the other hand, as results from previous studies indicate that individual stimulant drugs have similar effects, it seems justified to group them together (Kraemer & Maurer, 2002; Staack & Maurer, 2005) . Another limitation is that due to the cross-sectional design of the 48 study, conclusions about causality between stimulant use and cognitive functioning can not be drawn. Longitudinal studies and intervention studies are needed to determine whether these associations are caused by stimulant use or represent a pre-selection effect. Finally, the group of current stimulant users was relatively small compared to the lifetime frequent and lifetime infrequent groups. Although we did find large effect sizes in this group, a lack of power could have resulted in the absence of statistically significant associations.
These limitations notwithstanding, this study allowed us to expand the existing literature on the relationship between stimulant use and cognition. We were able to investigate a large sample of patients with non-affective psychotic disorders and their unaffected siblings. Moreover, our sample consisted of stimulant using and non-using healthy controls, making it the first study to assess the relationship between stimulant use and cognition in these three groups simultaneously. Furthermore, because of the naturalistic nature of our study, results may be easily generalized to everyday practice. Lastly, we carried out an extensive clinical assessment and a broad range of cognitive tests, which allowed us to assess associations with several cognitive domains while controlling for relevant confounders.
In conclusion, this is the first study to assess the association between stimulant use and cognitive functioning in three groups of individuals with varying levels of psychosis vulnerability. We found that frequent stimulant use may equally affect cognitive functioning in patients with non-affective psychosis, their unaffected siblings and healthy controls. Subjects with a lifetime history of frequent stimulant use were especially impaired in verbal memory, acquired knowledge and processing speed, while current stimulant users were impaired in verbal memory. Infrequent stimulant use was not associated with cognitive impairment in patients, their unaffected siblings and healthy controls. On the base of our findings, frequent stimulant use should be discouraged. More research on stimulant use and cognition needs to be performed to clarify contradictory results on this topic. Longitudinal studies investigating changes in stimulant use and cognitive functioning could provide more insight into the causes and consequences, clarifying the issue whether associations represent a direct cognitive effect of stimulant use or a selection effect. Furthermore, longitudinal research should determine wether these alterations in cognitive functioning persist over time or normalize after cessation of use.
